Biopsy Devices Competitive Landscape Report 2020

DelveInsight’s “Biopsy Devices Pipeline Insight and Competitive Landscape 2020,” report provides comprehensive insights about 20+ companies and 23+ pipeline devices in biopsy devices pipeline landscape.

Significant increase in incidence of cancer, such as breast, prostate, and lung, and rapid technological advancements such as 3D optical biopsies, MRI-targeted biopsies, and Ultrasound–guided biopsies fuel the adoption of biopsy devices.

Moreover, rise in awareness on diagnosis of chronic diseases fosters the demand for integrated biopsy technologies such as stereo-tactic-guided biopsy.

Click here and get access to Biopsy Devices Pipeline Report.

About Biopsy Devices

Biopsy devices are instruments that aid in the removal of tissue samples from the body. These samples are collected in order to examine it more closely.

When a Biopsy is needed?

· A mammogram shows a lump or mass, indicating the possibility of breast cancer

· A mole on the skin has changed shape recently and melanoma is possible

· A person has chronic hepatitis and it's important to know if cirrhosis is present

Request for a free sample report: https://www.delveinsight.com/sample-request/biopsy-devices-pipeline-insight-and-competitive-landscape

Biopsy Devices Competitive Assessment on the basis of:

· Product Type

Biopsy devices pipeline report is segmented based on product type such as core biopsy devices, aspiration biopsy needles and vacuum assisted biopsy devices.

· Product Technique

Based on the technology biopsy devices are of various types:

  1.  Ultrasound-guided     Biopsy
  2.  Stereotactic-guided     Biopsy
  3.  MRI-guided     Biopsy

The biopsy device pipeline assessment covers the entire types of these techniques.

· Product Application

The biopsy devices are used in breast biopsy, lung biopsy, colorectal biopsy and prostate biopsy. 

· Major Players in Biopsy Devices

There are approx. 20+ key companies which are developing the products for biopsy devices.

· 3D Biopsy Device: 3DBiopsy, Inc.

· The Osteo Access System: Actuated Medical

Biopsy Devices Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on:

· Brand Positioning of Leading companies

· Application

· Industry Collaborations

Download full report: https://www.delveinsight.com/report-store/biopsy-devices-pipeline-insight-and-competitive-landscape

 

 

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more